热门资讯> 正文
泰坦制药宣布纳斯达克不合规通知
2024-11-28 05:22
- Titan Pharmaceuticals (NASDAQ:TTNP) was notified by Nasdaq that it failed to file its Q3 report on time, violating listing requirements.
- The company has until January 21, 2025, to submit a plan to regain compliance. If Nasdaq accepts the plan, then Nasdaq may grant an exception of until May 19, 2025, to regain compliance.
- Nasdaq also notified the company that it no longer meets audit committee requirements following Brynner Chiam’s appointment as acting principal executive officer and acting principal financial officer.
- Titan Pharmaceuticals intends to appoint an additional independent director to the board and the audit committee.
- Source: Press Release
More on Titan Pharmaceuticals
- Financial information for Titan Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
